Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance

Amgen, Inc.Trade
Avalanche Treasury Corporation Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Amgen, Inc. trades at $416.52 (market cap $224.14B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $15.33M). The key difference: Amgen, Inc. is far larger — about 14621× Avalanche Treasury Corporation Class A Common Stock's market cap, and Amgen, Inc. pays a 2.43% dividend while Avalanche Treasury Corporation Class A Common Stock pays none. Which is the better fit depends on your goals.

AMGNAVAT
Market Cap
$224.14B$15.33M
Sector
HealthFinancials
52-Week High
$417.20$10.75
52-Week Low
$271.18$0.30
Enterprise Value
$267.45B$15.33M
Dividend Yield
2.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.

Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.

Avalanche Treasury Corporation Class A Common Stock

AVAT trades at $0.342, up 1.57% on the day, with a bearish technical signal from moving averages. The company reported a net income of $8.28 million for the current period but negative operating cash flow of -$930,710, indicating potential cash burn. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.

The outlook is mixed; a low P/B of 0.4 suggests potential undervaluation, but negative cash flow and a bearish technical trend pose risks. Investment opportunity hinges on the company's ability to improve operational efficiency post-listing, while risks include sustained cash burn and competitive pressures in treasury management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Avalanche Treasury Corporation Class A Common Stock

Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.

Read more on AVAT